Clinical Trial Update: PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease [Phase 2]

View source ↗

Summary

Clinical trial update for PREDICT-RD, a Phase 2 study assessing ctDNA surveillance in patients with residual disease in triple-negative breast cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Breast Cancer, Residual Disease | Phase 2 | Status: RECRUITING